Funded Tech Companies
bit.bio
Headquartered in Cambridge, bit.bio has funding from M&G Investments and private investors.
Company Overview
Company Name
bit.bio
Company Status
Private & Independent
Industry
Funding Rounds
Total Funding
Contact Information
Mailing Address
The Dorothy Hodgkin Building, Babraham Research Campus
Cambridge, CB22 3FH
UK
Cambridge, CB22 3FH
UK
Phone
Website
Email Address
Company Background Information
Overview
bit.bio is a synthetic biology company providing human cells for research, drug discovery and cell therapy. The company applies a patented safe harbour gene-targeting approach (opti-ox�; Pawlowski 2017) to inducibly express transcription factor combinations that reprogram human induced pluripotent stem cells (iPSCs) into highly defined and mature human cell types. The company has expertise in the underpinning science of synthetic biology and stem cells, manufacturing, and clinical translation. The board is chaired by Lord David Prior.
Profile
Social Media
Company News
Facebook
YouTube
Last Transaction
11/4/2026
Financing History
Date
Type
Amount
Management Team
Title
Name
Email & Social
Chief Executive Officer
Emma Pepperell
Chief Financial Officer
Sam Jones
Chief Operating Officer
Adam Rowe
Chief Technical Officer
Sejla Salic-Hainzl
VP - Bus. Development
Niv Pande
VP - General Counsel
Kai Gan
VP - Human Resources
Vicki Bell
VP - Sales
Connie O'Donnell
Company Investors
- M&G Investments
- Private Investors (Jonathan Milner)
Browse more funded tech companies:
Share this article
About Our Venture Capital Transactions Database
This tech company profile is powered by VentureDeal.com, a market leader in private equity transaction data.
Additional Resources for Entrepreneurs